Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Aminopeptidase PILS/ARTS1 Antibody, R&D Systems™

Rat Monoclonal Antibody
Supplier: R&D Systems MAB23341SP
This item is not returnable.
View return policy
Description
Aminopeptidase PILS/ARTS1 Monoclonal specifically detects Aminopeptidase PILS/ARTS1 in Human samples. It is validated for Immunocytochemistry.Specifications
Aminopeptidase PILS/ARTS1 | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. | |
Adipocyte-derived leucine aminopeptidase, A-LAP, A-LAPALAP, Aminopeptidase PILS, ARTS1, ARTS1aminopeptidase regulator of TNFR1 shedding, ARTS-1PILSAP, EC 3.4.11, EC 3.4.11.-, EC 3.4.11.1, endoplasmic reticulum aminopeptidase 1, endoplasmic reticulum aminopeptidase associated with antigen processing, ERAAP1, ERAP1, KIAA0525APPILS, PILS-AP, PILS-APERAAP, Puromycin-insensitive leucyl-specific aminopeptidase, Type 1 tumor necrosis factor receptor shedding aminopeptidase regulator | |
Mouse myeloma cell line NS0-derived recombinant human Aminopeptidase PILS/ARTS1, Thr25-Ile929, Accession # Q9NZ08 | |
25 μg | |
51752 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 6 months, -20 to -70°C under sterile conditions after reconstitution. | |
IgG2a |
Immunocytochemistry | |
325813 | |
Immunocytochemistry 8-25 μg/mL | |
Q9NZ08 | |
Rat | |
Protein A or G purified from hybridoma culture supernatant | |
Primary | |
Detects human Aminopeptidase PILS/ARTS1 in direct ELISAs. | |
Human | |
Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction